HDT Bio

HDT Bio Corp. focuses on the research and development of RNA, formulations, and auxiliary technologies, and is developing biotherapeutic technologies for oncology and infectious disease applications. The company primarily develops bioengineered immuno-oncology therapies that not only target cancer but also enhance the patient's own immune system. Our goal is to gain regulatory approval and establish regional partnerships for manufacturing and clinical development, ensuring that companies familiar with healthcare systems can maximize the availability of these drugs to patients.